
CEO World
Burger King Prepares for Shrinking Appetites Driven by GLP-1 Drugs
With 11% of U.S. adults now using GLP-1 medications, the fast-food industry faces a structural shift in consumer demand. Tom Curtis, president of Burger King for the U.S. and Canada, acknowledges the trend is poised to alter dining habits, forcing major chains to rethink portions and menu compositions to remain relevant.

























